Search

Your search keyword '"BROWN, PETER"' showing total 10 results
Start Over Author "BROWN, PETER" Language danish
10 results on '"BROWN, PETER"'

1. Diffust storcellet B-celle lymfom

Author

Nully Brown, Peter de, El-Galaly, Tarec Christoffer, Jørgensen, Judit, Clausen, Michael Rost, Larsen, Thomas Stauffer, Tholstrup, Dorte, Gang, Anne Ortved, Meidahl Petersen, Peter, and Hamilton-Dutoit, Stephen

Published
2022

2. Malignt Lymfom og CLL:National årsrapport 2020

Author

Nully Brown, Peter de, El-Galaly, Tarec Christoffer, Jørgensen, Judit, Kamper, Peter, Dessau-Arp, Andriette, Clausen, Michael Roost, Larsen, Thomas Stauffer, Poulsen, Christian Bjorn, Josefsson, Pär, Pedersen, Michael, Starklint, Jørn, Christensen, Rita, Steding-Jessen, Marianne, and Fredsted, Anne

Published
2021

3. Blodsygdomme

Author

Kjeldsen, Lars, Abildgaard, Niels, Andersen, Mette Klarskov, Birgens, Henrik, Brown, Peter De Nully, El-Galaly, Tarec Christoffer, Frederiksen, Henrik, Grønbæk, Kirsten, Hutchings, Martin, Leinøe, Eva Birgitte, Nielsen, Ove Juul, Niemann, Carsten Utoft, Overgaard, Ulrik, Sengeløv, Henrik, Stentoft, Jesper, Schaffalitzky de Muckadell, Ove B., Hastrup Svendsen, Jesper, and Vilstrup, Hendrik

Published
2019

4. Malignt Lymfom og CLL:National årsrapport 2016

Author

Brown, Peter de Nully, Jensen, Paw, Jørgensen, Judit, Pedersen, Per, Christensen, Jacob Haaber, Poulsen, Christian B, Josefsson, Pär, Pedersen, Michael, and Starklint, Jørn

Published
2017

8. [The Haematological Corporate Database].

Author

Brown Pde N, Nørgaard JM, Gimsing P, Hasselbalch H, Abildgård N, Jensen P, and Bukh A

Subjects
Denmark epidemiology, Humans, Quality Assurance, Health Care, Databases, Factual, Hematologic Diseases epidemiology, Registries
Published
2012

9. [Novel medical treatment modalities in hematology].

Author

Hasselbalch HC, Birgens H, Dufva IH, Dalseg AM, Brown Pde N, Jensen MK, and Vangsted A

Subjects
Aminoglycosides therapeutic use, Anemia, Hemolytic drug therapy, Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal, Murine-Derived, Benzamides, Benzoates therapeutic use, Boronic Acids therapeutic use, Bortezomib, Carbazoles therapeutic use, Carrier Proteins therapeutic use, Cyclophosphamide therapeutic use, Dasatinib, Furans, Gemtuzumab, Humans, Hydrazines therapeutic use, Imatinib Mesylate, Indoles therapeutic use, Lenalidomide, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Leukemia, Myeloid, Acute drug therapy, Multiple Myeloma drug therapy, Myelodysplastic Syndromes drug therapy, Piperazines therapeutic use, Purpura, Thrombocytopenic drug therapy, Pyrazines therapeutic use, Pyrazoles therapeutic use, Pyrimidines therapeutic use, Receptors, Fc therapeutic use, Recombinant Fusion Proteins, Rituximab, Thalidomide analogs & derivatives, Thalidomide therapeutic use, Thiazoles therapeutic use, Thrombopoietin, Vidarabine analogs & derivatives, Vidarabine therapeutic use, Antibodies, Monoclonal therapeutic use, Antineoplastic Agents therapeutic use, Hematologic Diseases drug therapy, Immunologic Factors therapeutic use, Leukemia drug therapy, Lymphoma drug therapy
Abstract

Today several monoclonal antibodies, including the anti-CD20 antibody (rituximab), the anti-CD52 antibody (alemtuzumab) and the anti-CD33 antibody (gemtuzumab ozogamacin) are all integrated in the therapeutic armamentarium of patients with malignant lymphoma, chronic lymphocytic leukaemia and acute myelogenous leukaemia, respectively. Rituximab has also been shown to be highly effective in the treatment of refractory autoimmune haemolytic anemias, idiopathic thrombocytopenia, and relapsing thrombotic thrombocytopenic purpura. New signal transduction inhibitors, dasatinib and nilotinib, are being used in patients with chronic myelogeneous leukaemia who develop resistance to imatinib. Thalidomide, lenalidomide and bortezomib have all been shown to be highly effective in multiple myeloma, and JAK2-inhibitors have entered phase II studies of patients with JAK2-positive primary myelofibrosis and related diseases.

Published
2008

10. [Radioimmunotherapy in non-Hodgkin's lymphoma. With focus on anti-CD20 treatment].

Author

de Nully Brown P, Jurlander J, Lindén O, and Hansen M

Subjects
Humans, Lymphoma, B-Cell radiotherapy, Lymphoma, Follicular radiotherapy, Antibodies, Monoclonal therapeutic use, Antigens, CD20 immunology, Antineoplastic Agents therapeutic use, Iodine Radioisotopes therapeutic use, Lymphoma, Non-Hodgkin radiotherapy, Radioimmunotherapy methods, Yttrium Radioisotopes therapeutic use
Abstract

Radioimmunotherapy in indolent NHL is a new and promising therapy which adds a new therapeutic tool to the treatment palette. Recent advantages in RIT are described and perspectives discussed.

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results